Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas
Clinical trial NCT02650999 · COMPLETED
Trial details
- NCT number
- NCT02650999
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2019-02-25
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.